Sequoia Capital China, China Merchants Health, Greenwoods Asset Management and Wuxi AppTec led a CNY1.2b (~USD188m) round for Stemirna Therapeutics, a China-based mRNA drugs and vaccines developer, with participation from OrbiMed, Advantech Capital, China Reform Fund, CMB International, Kaili Yifang Capital Management, Forebright Capital, CTS Capital and CITIC Securities Investment. Read more